In contrast, an inhibitor of the CXCL7 receptors CXCR1 and CXCR2 (SB225002) inhibited the proliferation of ccRCC cells and endothelial cells, thereby strongly suppressing tumor growth and aberrant tumor angiogenesis (Grépin et al., 2014). Here, CXCR2 is linked to neoplasm.